Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis
Authors:
- Robert LeadleyRLRobert Leadley
- Sangita BaxiSBSangita Baxi
- Waldemar WysokinskiWWWaldemar Wysokinski
- Robert McBaneRMRobert McBane
- 1 January 2008
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 99 (04) , 759-766
Abstract
The objective of this study was to determine if orally-administered PD0348292, a direct specific factor Xa inhibitor, inhibits thrombosis following porcine carotid arterial injury comparably to aspirin or clopidogrel alone or in combination. We further sought to determine whether the antithrombotic efficacy in vivo could be predicted using an ex-vivo perfusion chamber. Oral treatments included: PD0348292 (0.4, 0.9, or 4.3 mg/kg); PD0348292 (0.4 mg/kg) plus aspirin (325 mg); aspirin; clopidogrel (75 mg); aspirin plus clopidogrel; or vehicle (n=6–10/group). Aspirin and clopidogrel were administered 27 and four hours pre-injury and PD0348292 or vehicle was administered four hours pre-injury. Both carotid arteries were crush-injured, and thrombus was measured by detection of 111In-platelets over 30 minutes. Prior to injury, the antithrombotic efficacy was assessed by ex-vivo perfusion chamber platelet deposition. PD0348292 produced dose-dependent prothrombin time (0.9- to 2.9-fold) and aPTT (1.4- to 2.5-fold) prolongations. Bleeding times were significantly prolonged in each active drug group compared to vehicle, but were not significantly different between drug groups. PD0348292 significantly inhibited arterial platelet deposition (x106/cm2) at 4.3(549 ± 1,066), 0.9 (399 ± 162) and 0.4 mg/kg (531 ± 470) compared to vehicle (2,242 ± 1,443). Aspirin (992 ± 973), clopidogrel (537 ± 483), clopidogrel plus aspirin (228 ± 66) or PD0348292 plus aspirin (558 ± 317) also significantly inhibited platelet deposition, although these values were not significantly different than with any dose of PD348292. Perfusion chamber platelet deposition correlated significantly with in-vivo anti-thrombotic response. In conclusion, PD0348292 inhibited arterial thrombosis comparable to aspirin plus clopidogrel. Perfusion chamber methodology may be useful in predicting in-vivo antithrombotic efficacy.Keywords
This publication has 14 references indexed in Scilit:
- Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patientsThrombosis and Haemostasis, 2007
- Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid StenosisNew England Journal of Medicine, 2006
- Co-crystal Structure and Inhibition of Factor Xa by PD0313052 Identifies Structurally Stabilized Active Site Residues of Factor Xa and ProthrombinaseBiochemistry, 2005
- Inhibition and reversal of platelet‐rich arterial thrombus in vivo: direct vs. indirect factor Xa inhibitionJournal of Thrombosis and Haemostasis, 2004
- Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial InfarctionCirculation, 2004
- A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular diseaseJACC, 2003
- Influence of Anatomical Location on Arterial ThrombosisArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Effect of Selective Factor Xa Inhibition on Arterial Thrombus Formation Triggered by Tissue Factor/Factor VIIa or Collagen in an Ex Vivo Model of Shear-Dependent Human ThrombogenesisArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Gating of thrombin in platelet aggregates by pO2-linked lowering of extracellular Ca2+ concentrationBiochemistry, 1995
- Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patientsThrombosis Research, 1993